What is the history of Cohen Syndrome?

Cohen Syndrome was first described in the medical literature in 1973 by Michael M. Cohen Jr. and colleagues, who identified a distinct pattern of intellectual disability, microcephaly, and characteristic facial features. Since its initial discovery, our understanding of Cohen Syndrome has evolved from a purely observational clinical diagnosis to a condition understood through its underlying genetic mutation in the VPS13B (formerly COH1) gene.

When and how was Cohen Syndrome first identified?

In 1973, Dr. Michael M. Cohen Jr. and his team reported on two children who exhibited a unique constellation of symptoms, including hypotonia, intellectual disability, and specific craniofacial anomalies. Initially, clinicians relied solely on physical examination to diagnose Cohen Syndrome, which often led to confusion with other syndromes presenting with similar developmental delays. It was not until the early 2000s that researchers pinpointed the genetic basis, providing a definitive tool for diagnosis.

How has our understanding of Cohen Syndrome evolved?

For decades, Cohen Syndrome was characterized primarily by its phenotype. The medical community initially struggled to distinguish it from other neurodevelopmental disorders. The major turning point occurred in 2003, when researchers identified mutations in the VPS13B gene on chromosome 8q22. This discovery shifted Cohen Syndrome from a mystery of clinical observation into a well-defined autosomal recessive condition, allowing for accurate genetic counseling and prenatal testing.

What are the major milestones in the history of the condition?

• 1973: First clinical description of Cohen Syndrome published by Cohen et al.


• 2003: Identification of the VPS13B gene as the causative factor.


• 2010s-Present: Increased focus on multidisciplinary management, including early intervention therapies to address the specific needs of individuals living with Cohen Syndrome.

How has patient advocacy changed the landscape?

Early historical accounts often focused on clinical deficits, but the rise of patient advocacy groups has shifted the focus toward quality of life. Within the DiseaseMaps.org community, 118 people with Cohen Syndrome have shared their experiences, creating a vital network of support that did not exist in the 1970s. This community-driven data helps researchers better understand the variability of Cohen Syndrome across different populations.

Next steps

• Consult with a clinical geneticist to discuss genetic testing options for Cohen Syndrome.


• Connect with the 118 members of our community at DiseaseMaps.org to share experiences and coping strategies.


• Engage with pediatric specialists to establish a multidisciplinary care plan.

Medical disclaimer: This content is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Cohen Syndrome


• OMIM (Online Mendelian Inheritance in Man): Entry #216550


• Orphanet: Rare disease database, ORPHA193


• PubMed: "Cohen syndrome: A clinical and genetic review"